Researchers at The University of Texas at Austin, including Texas ChE’s Dr. George Georgiou and Dr. Jennifer Maynard, successfully culminated years of work when a drug they engineered for the treatment and prevention of inhalational anthrax — the anthrax antitoxin obiltoxaximab — received approval March 21 from the U.S. Food and Drug Administration (FDA). Part of the molecule was engineered at UT Austin before being licensed to New Jersey-based pharmaceutical company Elusys Therapeutics for further development. It will be sold under the name Anthim.
- New cancer treatment uses enzymes to boost immune system...August 29, 2018 - 2:18 pm
- GRA George Delidakis wins Poster Prize at EMBO Antibodies...August 21, 2018 - 6:56 pm
- Dr. Erik Johnson accepts Data Scientist position at Epic...August 17, 2018 - 3:52 pm
- Dr. Joseph Dekker accepts Sr. Scientist position at Molecular...August 17, 2018 - 3:21 pm